ERBB2 and breast carcinoma: Importantly, we used two separate HER2-positive cell lines (one luminal B subtype and one HER2-positive subtype) and thus are confident that our findings in relation to JAM/HER2 crosstalk and the relevance of JAM-A cleavage to drug resistance were not an artefact of one cell line or breast cancer molecular subtype.